Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Cynthia D. Guy"'
Sex and Menopause Modify the Effect of Single Nucleotide Polymorphism Genotypes on Fibrosis in NAFLD
Autor:
Jiayin Zheng, Anna Mae Diehl, Cynthia D. Guy, Ayako Suzuki, Kara Wegermann, Allison E. Ashley-Koch, Shein-Chung Chow, Andrea D. Coviello, Melanie E. Garrett, Cynthia A. Moylan, Manal F. Abdelmalek
Publikováno v:
Hepatology Communications, Vol 5, Iss 4, Pp 598-607 (2021)
Hepatology Communications
Hepatology Communications
The development of fibrosis in nonalcoholic fatty liver disease (NAFLD) is influenced by genetics, sex, and menopausal status, but whether genetic susceptibility to fibrosis is influenced by sex and reproductive status is unclear. Our aim was to iden
Autor:
Mathew M. Yeh, Cynthia D. Guy, Patricia Belt, Ryan M. Gill, Danielle Carpenter, Oscar W. Cummings, Laura A. Wilson, Daniela S. Allende, David E. Kleiner, Cynthia Behling, Samer Gawrieh, Mark L. Van Natta, Naga Chalasani
Publikováno v:
Liver International
Background/Aims Glycogen synthesis and storage are normal hepatocyte functions. However, glycogenosis, defined as excess hepatocyte glycogen visible by routine H&E light microscopy, has not been well characterized in nonalcoholic fatty liver disease
Autor:
Anna Mae Diehl, Oliver Glass, Elizabeth Bechard, Jane F. Pendergast, Cynthia D. Guy, Daniel Liu, Manal F. Abdelmalek
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Hepatology Communications, Vol 6, Iss 2, Pp 334-344 (2022)
Exercise is a foundational treatment for nonalcoholic fatty liver disease (NAFLD); however, the majority of patients are unable to initiate and maintain effective exercise habits and remain at increased risk for progressive liver disease. Barriers an
Autor:
Wing-Kin Syn, Keyur Patel, Cynthia D. Guy, Anna Mae Diehl, Robert D. Streilein, Ricardo Henao, Oliver Glass, Hans J Gruss, Manal F. Abdelmalek, Cynthia A. Moylan, Russell P. Hall
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 2, Iss 11, Pp 1344-1355 (2018)
Hepatology Communications, Vol 2, Iss 11, Pp 1344-1355 (2018)
The severity of hepatic fibrosis is the primary predictor of liver‐related morbidity and mortality in patients with nonalcoholic fatty liver disease (NAFLD). Unfortunately, noninvasive serum biomarkers for NAFLD‐associated fibrosis are limited. W
Autor:
Sarah E. Kleinstein, David Goldstein, Cynthia A. Moylan, Cynthia D. Guy, Anna Mae Diehl, Manal F. Abdelmalek, Matthew Rein
Publikováno v:
Hepatology Communications
Hepatology Communications, Vol 2, Iss 9, Pp 1021-1029 (2018)
Hepatology Communications, Vol 2, Iss 9, Pp 1021-1029 (2018)
Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease with highly variable outcomes. Patients with simple steatosis typically experience a benign course, whereas those with more advanced liver injury, nonalcoholic steatohepatitis (NASH)
Autor:
Ying Wang, Anna Mae Diehl, Ricardo Henao, Manal F. Abdelmalek, Keri A. Seymour, Ranjan Sudan, Matthew J Crowley, Cynthia D. Guy, Anastasia-Stefania Alexopoulos, Dana Portenier, Andrea D. Coviello
Publikováno v:
Diabetes. 69
T2DM increases risk for advanced fibrosis in NAFLD, however little is known about the impact of glycemic control on fibrosis severity. Objective: To assess whether glycemic control is associated with severity of fibrosis in NAFLD. Methods: We utilize
Autor:
Kristin Nelson, Hsiao D. Lieu, Mildred Gottwald, James F. Trotter, Guy W. Neff, Nadege Gunn, Alex M. DePaoli, Sam E. Moussa, Ziad Younes, Andrew Yan, Mustafa R. Bashir, Angelo H. Paredes, Juan P. Frias, William C.G. Chang, Cynthia D. Guy, Stephen A. Harrison, Lei Ling, Anita Kohli
Publikováno v:
Gastroenterology. 160(1)
Background & Aims Aldafermin, an engineered analog of fibroblast growth factor 19, inhibits bile acid synthesis and regulates metabolic homeostasis. We report results from a 24-week, phase 2 study, with serial liver biopsies, of patients with nonalco
Autor:
Cynthia D. Guy, Claire Faulkner, Manal F. Abdelmalek, Larry Mimms, Ranjan Sudan, Anna Mae Diehl, Anjali Jain, Xiao-jun Li, Lauren Okada, Dana Portenier, S Singh, Lisa Richards, Rohit Loomba, Kelly D. Hester
Publikováno v:
Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, vol 17, iss 9
Background & Aims We analyzed markers of fibrosis in serum samples from patients with nonalcoholic fatty liver disease (NAFLD), assessed by liver biopsy. We used serum levels of markers to develop an algorithm to discriminate patients with advanced f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b31f3804628ef5863ad3bbb749e54907
https://escholarship.org/uc/item/0b04137v
https://escholarship.org/uc/item/0b04137v
Autor:
Sam E. Moussa, Rong Zhou, Juan P. Frias, Mustafa R. Bashir, Cynthia A. Moylan, Rebecca Taub, Stephen A. Harrison, Seth J. Baum, Cynthia D. Guy, Meena B. Bansal, Naim Alkhouri, Brent A. Neuschwander-Tetri
Publikováno v:
Lancet (London, England). 394(10213)
Non-alcoholic steatohepatitis (NASH) is characterised by hepatic steatosis, inflammation, hepatocellular injury, and progressive liver fibrosis. Resmetirom (MGL-3196) is a liver-directed, orally active, selective thyroid hormone receptor-β agonist d
Autor:
Stephen A. Harrison, Stephen J. Rossi, Lei Ling, Sandra Owers, Rajarshi Banerjee, Bryan Baxter, Mark J. Jaros, James F. Trotter, Cynthia D. Guy, Alex M. DePaoli, Mustafa R. Bashir, Angelo H. Paredes
Publikováno v:
Hepatology (Baltimore, Md.). 71(4)
NGM282, an engineered fibroblast growth factor 19 analogue, rapidly and significantly reduced liver fat content in a multicenter, randomized, double-blind, placebo-controlled study in patients with biopsy-confirmed nonalcoholic steatohepatitis (NASH)